Late-stage biotech developing in-licensed therapies for inflammatory diseases.
Industry: Health Care
Latest Trade: $5.99 +0.17 (+2.9%)
First Day Return: +30.6%
Return from IPO: -67.7%
Industry: Health Care
IPO Data | |
---|---|
IPO File Date | 04/13/2023 |
Offer Price | $18.00 |
Price Range $16.00 - $18.00 | |
Offer Shares (mm) | 30.0 |
Deal Size ($mm) | $540 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
IPO Data | |
---|---|
IPO Date | 05/04/2023 |
Offer Price | $18.00 |
Price Range $16.00 - $18.00 | |
Offer Shares (mm) | 30.0 |
Deal Size ($mm) | $540 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
Underwriters |
---|
Morgan Stanley |
Jefferies |
more |
Company Data | |
---|---|
Headquarters | Agoura Hills, CA, United States |
Founded | 2020 |
Employees at IPO | 51 |
Website www.acelyrin.com |